Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Leucht

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
The Cochrane Database of Systematic Reviews|October 30, 2003
New generation antipsychotics for first episode schizophreniaC Rummel, J Hamann, W Kissling, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 20, 2001
Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapyW Steimer, B Müller, S Leucht, et al.
The Pharmacogenomics Journal|May 20, 2009
Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?B Laika, S Leucht, S Heres, et al.
Fortschritte Der Neurologie-Psychiatrie|May 25, 2013
Pharmacological treatment of schizophreniaS Leucht, S Heres, W Kissling, et al.
Schizophrenia Research|February 16, 1999
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trialsS Leucht, G Pitschel-Walz, D Abraham, et al.
Acta Psychiatrica Scandinavica|December 5, 2013
Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?C Corves, R R Engel, J Davis, et al.
The Pharmacogenomics Journal|July 29, 2009
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcomeB Laika, S Leucht, S Heres, et al.
Acta Psychiatrica Scandinavica|October 9, 2007
Physical illness and schizophrenia: a review of the literatureS Leucht, T Burkard, J Henderson, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|November 12, 2010
Drowning in numbers-what psychiatrists mean when talking to patients about probabilities of risks and benefits of medicationJ Hamann, R Mendel, M Bühner, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|June 16, 2004
Language bias in neuroscience--is the Tower of Babel located in Germany?S Heres, S Wagenpfeil, J Hamann, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
The Cochrane Database of Systematic Reviews|October 30, 2003
New generation antipsychotics for first episode schizophreniaC Rummel, J Hamann, W Kissling, et al.
Clinica Chimica Acta; International Journal of Clinical Chemistry|June 20, 2001
Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapyW Steimer, B Müller, S Leucht, et al.
The Pharmacogenomics Journal|May 20, 2009
Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?B Laika, S Leucht, S Heres, et al.
Fortschritte Der Neurologie-Psychiatrie|May 25, 2013
Pharmacological treatment of schizophreniaS Leucht, S Heres, W Kissling, et al.
Schizophrenia Research|February 16, 1999
Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trialsS Leucht, G Pitschel-Walz, D Abraham, et al.
Acta Psychiatrica Scandinavica|December 5, 2013
Do patients with paranoid and disorganized schizophrenia respond differently to antipsychotic drugs?C Corves, R R Engel, J Davis, et al.
The Pharmacogenomics Journal|July 29, 2009
Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcomeB Laika, S Leucht, S Heres, et al.
Acta Psychiatrica Scandinavica|October 9, 2007
Physical illness and schizophrenia: a review of the literatureS Leucht, T Burkard, J Henderson, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|November 12, 2010
Drowning in numbers-what psychiatrists mean when talking to patients about probabilities of risks and benefits of medicationJ Hamann, R Mendel, M Bühner, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|June 16, 2004
Language bias in neuroscience--is the Tower of Babel located in Germany?S Heres, S Wagenpfeil, J Hamann, et al.
Pageof 8